What Destum Partners does

Destum Partners is a boutique advisory and consulting firm founded in 2006 and headquartered in Charlotte, North Carolina, serving biopharmaceutical and life sciences companies globally. The firm operates two integrated practices: an Advisory Practice that provides transaction advisory services including licensing agreements, asset acquisitions, and co-development arrangements (40+ transactions closed with cumulative deal value exceeding $5.25 billion), and a Consulting Practice powered by Σ dp Analytics, which delivers scientific, market, commercial, and financial expertise through product and market assessments and asset valuations using rNPV and DCF methodologies. Additional proprietary products include KOL CONTACT (a Key Opinion Leader database initially focused on U.S. oncology) and MediCalculate (a licensing terms benchmarking tool).

The firm is entirely owned by its three Managing Directors — Gareth Lugg (Co-Founder), Tom Filipczak, and Matthew Vanderberg — who collectively bring over 60 years of combined industry experience from prior roles at Morgan Stanley, Smith Barney, Pfizer, Roche, Novartis/Sandoz, Wachovia, and Bank of America. Destum Partners serves a clientele ranging from multinational Fortune 500 pharmaceutical companies to mid-sized and early-stage privately held biotechs, with operating geographies spanning the Americas, Europe, Asia, and Oceania.

Revenue is generated through transaction-based advisory fees (success fees on closed licensing and M&A deals) and professional-services consulting engagements, both delivered through a direct, senior-led engagement model. The firm employs approximately 9-12 people, operates without external venture or private equity backing, and markets primarily through industry conferences (BIO, Bio-Europe, JPM Healthcare), press releases on closed transactions, and its corporate website. It is selective in its client portfolio, positioning its integrated consulting-plus-advisory model as a differentiated value proposition in a sector where most competitors offer only one of the two services.

Name

Destum Partners

Legal name

Destum Partners, Inc.

Website

https://destumpartners.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

Destum Partners is a privately held boutique advisory and consulting firm founded in 2006 in Charlotte, NC, providing integrated transaction advisory and strategic consulting services to biopharmaceutical and life sciences companies worldwide, having closed 40+ deals worth over $5.25 billion.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Advisory Services

NAICS

Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Management Consulting Services (8742), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Industry-Specialist / Sector-Focused M&A Advisory (FSAEAGAJ)

Keywords

• Biopharma advisory services
• Transaction advisory
• Licensing consulting
• Life sciences consulting
• Asset valuation services

Headquarters

HQ city

Charlotte

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Advisory Services: Advisory practice focused on transactions including licensing agreements, acquisitions, and partnerships. They have completed 40+ transactions worth over $5.25B. Deal types include licensing agreements, asset acquisitions, and co-development arrangements.
2. Consulting Services: Consulting services powered by Σ dp Analytics, providing scientific, market, commercial, and financial expertise. Services include Product & Market Assessments and Asset Valuations using methodologies such as rNPV and DCF.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Destum Partners provides strategic advisory and consulting services to biopharmaceutical and life sciences companies. The firm operates two integrated practices: an Advisory Practice that represents buyers or sellers in transactions (licensing agreements, acquisitions, co-development arrangements) and a Consulting Practice powered by Σ dp Analytics that delivers scientific, market, commercial, and financial expertise through product and market assessments and asset valuations.

Product overview

Destum Partners is a boutique advisory and consulting firm that offers two integrated service practices. The Advisory Practice provides transaction/deal advisory services for biopharma and life sciences companies, having completed over 42 transactions worth over $5.25B. The Consulting Practice, powered by Σ dp Analytics, delivers strategic consulting through product and market assessments and asset valuations using methodologies like rNPV and DCF. Additional products include KOL CONTACT (a Key Opinion Leader database) and MediCalculate (a licensing terms negotiation tool).

Differentiator

Problem solved

Functional benefit

Products and services

• Advisory Practice
• Consulting Practice
• KOL CONTACT

Quantifiable outcome

• Completed over 42 transactions worth over $5.25B
• +1 more outcomes

Named customers16 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eleven partnerships are on record, tiered flagship, notable, core and minor.

• Angelini Pharma and Quiver BioscienceflagshipStrategic or Co-development Partner · 23 February 2026Destum Partners acted as transaction advisor to Quiver Bioscience in a multi-year collaboration and licensing agreement. Quiver will receive undisclosed advance payment plus milestone payments of up to $120 million and royalties. The partnership focuses on discovering and advancing novel therapeutics for Developmental and Epileptic Encephalopathies (DEEs), a group of rare genetic diseases causing severe treatment-resistant seizures in children.
• Quiver Bioscience and QurAlisnotableStrategic or Co-development Partner · 1 February 2026Destum Partners acted as transaction advisor to Quiver Bioscience in a research collaboration to advance novel gene-targeted therapeutic approach for Fragile X syndrome treatment. Combines Quiver's GPS platform with QurAlis' precision medicine expertise.
• EffRx Pharmaceuticals and Compai PharmanotableChannel Partner/ Reseller/ Distributor · 8 January 2026Destum Partners acted as exclusive advisor to Compai Pharma for exclusive licensing and distribution agreement to commercialize BINOSTO in Malaysia for osteoporosis treatment.
• AcuraStem and TakedacoreStrategic or Co-development Partner · 25 September 2023Destum Partners acted as transaction advisor to AcuraStem in a license agreement where Takeda received exclusive worldwide license to AcuraStem's PIKFYVE program. AcuraStem received upfront and milestone payments totaling up to approximately $580 million plus tiered royalties. The program focuses on a novel therapeutic target for ALS and TDP-43 proteinopathies.
• EffRx Pharmaceuticals and Radius HealthcoreChannel Partner/ Reseller/ Distributor · 19 September 2023Destum Partners acted as exclusive advisor to EffRx for an exclusive licensing and distribution agreement where Radius received rights to commercialize BINOSTO in the United States for osteoporosis treatment.
• BIORCHESTRA and Global Biopharma CompanycoreStrategic or Co-development Partner · 27 March 2023Destum Partners acted as transaction advisor to BIORCHESTRA in an exclusive research, option, and licensing agreement worth up to $861M for CNS-targeted polymeric nanoparticle delivery of nucleic acid therapies. Collaboration focuses on initial target with option to expand to several additional targets.
• Hovione and JIXINGnotableStrategic or Co-development Partner · 20 May 2022Destum Partners acted as business development and licensing transaction advisor to Hovione in an exclusive global license agreement for JX08, a preclinical ophthalmology program. JIXING received global rights and leads full lifecycle from preclinical through commercialization.
• BIORCHESTRA and SK BiopharmaceuticalsnotableStrategic or Co-development Partner · 4 January 2022Destum Partners served as advisor to BIORCHESTRA in a research collaboration to develop miRNA-targeted therapeutics for epilepsy treatment. SK Biopharmaceuticals validates disease-modifying targets and conducts preclinical studies. Joint ownership of IP and licensing rights to discovered compounds.
• Antios Therapeutics and IRBM/INGM/OSRnotableStrategic or Co-development Partner · 15 November 2021Destum Partners acted as business development advisor to Antios for acquiring IP rights to fourth-generation HBV capsid assembly modulators (CAMs) from Italian sellers/parties. Total potential value of up to $50 million plus royalties.
• PAION AG and La Jolla PharmaceuticalnotableChannel Partner/ Reseller/ Distributor · 12 January 2021Destum Partners advised PAION on exclusive licensing agreement for GIAPREZA and XERAVA in Europe. La Jolla received $22.5 million upfront and up to $109.5 million in commercial milestones plus royalties (15% for XERAVA, 18-24% for GIAPREZA).
• Hammock Pharmaceuticals and Daré BioscienceminorChannel Partner/ Reseller/ Distributor · 6 December 2018Destum Partners advised Hammock Pharmaceuticals on licensing sale of global rights to MP-101 for bacterial vaginosis treatment and underlying hydrogel drug delivery technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Locust Walk: Boutique life sciences transaction advisory firm offering M&A, licensing, and strategic advisory to biopharma companies. Directly comparable to Destum Partners in target client (biotech and pharma), service mix (licensing and M&A advisory), and boutique scale.
• Outcome Capital: Life sciences advisory firm focused on strategic transactions, licensing, and M&A for healthcare and biotech clients. Comparable in mandate type, target market, and boutique positioning.
• Torreya Partners: Healthcare and life sciences M&A advisory firm serving pharma, biotech, and specialty companies. Highly comparable in sector focus and deal-driven advisory model.
• Back Bay Life Science Advisors: Boutique life sciences consulting and advisory firm providing strategic, transactional, and valuation services to biopharma. Closely comparable to Destum in integrated consulting-plus-advisory model and therapeutic-area-agnostic positioning.
• Health Advances: Life sciences strategy consulting firm serving pharma, biotech, and medtech on market assessments, valuations, and transaction support. Comparable in consulting-side offerings (Product & Market Assessments, Asset Valuations) using methodologies like rNPV.
• ClearView Healthcare Partners: Life sciences consulting firm focused on commercial strategy, market assessment, and transaction support for biotech and pharma. Comparable in therapeutic-area breadth, scientific rigor, and boutique client-service model.
• Aquilo Partners: Life sciences-focused investment bank advising biotech and pharma on M&A, licensing, and financing. Comparable in boutique deal advisory model and mid-market biopharma client base.
• Trinity Partners: Life sciences consulting firm providing strategy, transaction, and commercial advisory to biotech and pharma companies. Comparable in therapeutic-area-agnostic consulting and advisory model.

Broad incumbents

• L.E.K. Consulting: Global management consulting firm with a significant life sciences practice covering strategy, M&A, and licensing. Comparable in serving biopharma advisory and consulting needs but operates at much larger scale and offers a broader portfolio of services.

Emerging players

• Alacrita Consulting: Life sciences consulting firm offering commercial, scientific, and strategic advice to biotech and pharma. Comparable in boutique consulting-plus-advisory positioning but smaller scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Destum Partners